HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlon

This article was originally published in The Rose Sheet

Executive Summary

U.S. market share of the Revlon and Almay brands combined declined 5.3% to 21.3% in the third quarter. Revlon share did not decline by 5.3% and Almay share did not drop by 21.3% as reported in the Nov. 22 issue of "The Rose Sheet" (1"The Rose Sheet" Nov. 22, 2004, p. 4)...

You may also be interested in...



Revlon Initiates Ad Campaign Review

Revlon will undertake a review of its existing ad campaign, indicating the company may be looking to reposition its marketing approach as it continues to struggle to jumpstart sales

US Bill Urges Automatic Insulin Interchangeability

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel